Compare METCB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METCB | AKBA |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.9M | 729.1M |
| IPO Year | N/A | 2014 |
| Metric | METCB | AKBA |
|---|---|---|
| Price | $11.82 | $1.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $38.69 | $6.25 |
| AVG Volume (30 Days) | 96.0K | ★ 4.0M |
| Earning Date | 10-27-2025 | 11-10-2025 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $579,503,000.00 | $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | $21.27 | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $5.86 | $1.45 |
| 52 Week High | $21.80 | $4.08 |
| Indicator | METCB | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 40.49 |
| Support Level | $11.10 | $1.45 |
| Resistance Level | $12.78 | $1.61 |
| Average True Range (ATR) | 0.85 | 0.08 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 22.17 | 62.75 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.